Glucagon
Glycogenolytic Hormones
Sold as Baqsimi · OGLUO
- Drug class
- Glycogenolytic Hormones
- Availability
- Prescription only
- Routes
- Nasal
- Markets covered
- 4
- Products on record
- 18
- FDA reports (12 mo)
- 319
Overview
Glucagon is an active pharmaceutical ingredient in the Glycogenolytic Hormones group (H04AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 14 | May 15, 2026 |
| EU European Union | EMA | 2 | September 17, 2025 |
| US United States | FDA | 1 | December 15, 2024 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
GBUnited Kingdom· MHRA
14 products
Uses
Therapeutic indication GlucaGen is indicated for treatment of severe hypoglycaemic reactions, which may occur in the management of insulin treated children and adults with diabetes mellitus. Diagnostic indication GlucaGen is indicated for motility inhibition in examinations of the gastrointestinal tract in adults.
How to take
EUEuropean Union· EMA
2 products
Uses
Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
How to take
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE Glucagon for Injection is an antihypoglycemic agent and a gastrointestinal motility inhibitor indicated: • for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes. 1 ) • as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.
1 Severe Hypoglycemia Glucagon for Injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus. 2 Diagnostic Aid Glucagon for Injection is indicated as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.
How to take
CACanada· Health Canada
1 product
Uses
BAQSIMI is indicated for the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates. 1 Pediatrics Pediatrics (<18 years of age): BAQSIMI is indicated in children 4 years and above.
BAQSIMI has not been studied in pediatric patients less than 4 years of age. The number of pediatric patients (4 to <18 years) included in the clinical trials is limited (n=48) (see WARNINGS AND PRECAUTIONS, Special Populations, DOSAGE AND ADMINISTRATION, ACTION AND CLINICAL PHARMACOLOGY, and CLINICAL TRIALS).
2 Geriatrics Geriatrics (≥65 years of age): Clinical studies of BAQSIMI did not include sufficient numbers of subjects aged 65 and over. Limited clinical trial experience with BAQSIMI has not identified differences in responses between the elderly and younger patients (see WARNINGS AND PRECAUTIONS, Special Populations; DOSAGE AND ADMINISTRATION; and ACTION AND CLINICAL PHARMACOLOGY).
Drug interactions
Known interactions involving Glucagon. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL046680027 · revised May 15, 2026
- [2]European Medicines Agency · EMEA/H/C/005391 · revised September 17, 2025
- [3]FDA DailyMed · 15b49500-0aae-4e… · revised December 15, 2024 [PDF]
- [4]Health Canada (DPD) · 02492415 · revised March 22, 2025
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.